1215552-03-6
1215552-03-6
Chemical Structure
Riluzole-13C,15N2
Synonym(s): PK 26124-13C,15N2
- CAS No.: 1215552-03-6
- Formula:C713CH5F315N2OS
- Molecular Weight:237.18
IUPAC Name: 6-(trifluoromethoxy)benzo[d]thiazol-2-13C-3-15N-2-amine-15N
InChIKey: FTALBRSUTCGOEG-VUJIMZNRSA-N
SMILES: [15NH2][13C]1=[15N]C2=CC=C(OC(F)(F)F)C=C2S1
Biological Activity: Riluzole-13C,15N2 is the 13C and 15N labeled Riluzole[1]. Riluzole is an anticonvulsant agent and belongs to the family of use-dependent Na+ channel blocker which can also inhibit GABA uptake with an IC50 of 43 μM[2][3].
| Cat. No. | Product Name | Purity | Description | Pricing | |||||||||||||||||||
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
|
|
Riluzole-13C,15N2 | 99.90% | Riluzole-13C,15N2 is the 13C and 15N labeled Riluzole. Riluzole is an anticonvulsant agent and belongs to the family of use-dependent Na+ channel blocker which can also inhibit GABA uptake with an IC50 of 43 μM. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Riluzole (Standard) | 99.82% | Riluzole (Standard) is the analytical standard of Riluzole. This product is intended for research and analytical applications. Riluzole is an anticonvulsant agent and belongs to the family of use-dependent Na+ channel blocker which can also inhibit GABA uptake with an IC50 of 43 μM. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Riluzole-13C6 | Riluzole-13C6 (PK 26124-13C6) is 13C labeled Riluzole. Riluzole is an anticonvulsant agent and belongs to the family of use-dependent Na+ channel blocker which can also inhibit GABA uptake with an IC50 of 43 μM. | |||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
|
|
Riluzole | 99.75% | Riluzole is an anticonvulsant agent and belongs to the family of use-dependent Na+ channel blocker which can also inhibit GABA uptake with an IC50 of 43 μM. | ||||||||||||||||||||
|
loading...
/
|
|||||||||||||||||||||||
References
- [1]. Russak EM, et al. Impact of Deuterium Substitution on the Pharmacokinetics of Pharmaceuticals. Ann Pharmacother. 2019 Feb;53(2):211-216. [Content Brief]
- [2]. He Y, et al. Neuroprotective agent riluzole potentiates postsynaptic GABA(A) receptor function. Neuropharmacology. 2002 Feb;42(2):199-209. [Content Brief]
- [3]. Thompson JM, et al. Small-conductance calcium-activated potassium (SK) channels in the amygdala mediate pain-inhibiting effects of clinically available riluzole in a rat model of arthritis pain. Mol Pain. 2015 Aug 2811:51. [Content Brief]
